Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evusheld for Prevention of COVID-19 in Immuno-Suppressed Cancer Patients
NCT05438498Phase 3Terminated
- Sponsor
- MediMergent
- Start
- Jun 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by MediMergent. Primary endpoint: Serum Concentration of Evusheld (AZD7442) at 12 months. Started Jun 2022; status: terminated.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05438498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438498.